Upstream Bio, Inc. (UPB)

NMS – Real vaqt narxi. Valyuta: USD

6.75

+0.39 (6.13%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

6.96

+0.21 (3.11%)

Bozordan keyin: Jun 26, 2026, 7:09 PM EDT

14.06.2026

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

12.06.2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction sponsored by Onslow Bay Financial LLC, that is fully originated and serviced by AmeriHome Mortgage Company, LLC (AmeriHome). This transaction is comprised of 599 residential mortgages with an aggregate unpaid principal balance (UPB) of approximately $340.0 million as of the June 1, 2026 cut-off date. The underlying collateral.

10.06.2026

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey, on Sunday, June 14, 2026.

03.06.2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m.

29.05.2026

Upstream Bio: The Reset Is The Opportunity, Initiating At Buy

I am initiating a Buy rating on Verekitug, the lead asset of Upstream Bio, a small-cap biotech trading at an enterprise value under $200M. Verekitug's quarterly dosing and differentiated TSLPR mechanism offer competitive efficacy in severe asthma and CRSwNP, with strong phase 2 data supporting further development. UPB's key catalysts include FDA interactions, phase 3 trial initiations in 2027, and a COPD phase 2 readout, all of which could drive significant re-rating.

18.05.2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –

Videolar

No Data

There is no data to display

Press-relizlar

14.06.2026

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

12.06.2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

08.06.2026

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

18.05.2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio, Inc. (UPB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Upstream Bio, Inc. (UPB)

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Upstream Bio: The Reset Is The Opportunity, Initiating At Buy

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Videolar

No Data

Press-relizlar

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Upstream Bio: The Reset Is The Opportunity, Initiating At Buy

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Videolar

No Data

Press-relizlar

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Search stocks

Upstream Bio, Inc. (UPB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Upstream Bio, Inc. (UPB)

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Upstream Bio: The Reset Is The Opportunity, Initiating At Buy

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Videolar

No Data

Press-relizlar

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Upstream Bio: The Reset Is The Opportunity, Initiating At Buy

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Videolar

No Data

Press-relizlar

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference